Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0BAANV)

ADC Name	AbGn-7
Synonyms	AbGn 7; AbGn-7; AbGn7 Click to Show/Hide
Organization	AbGenomics International, Inc.
Drug Status	Phase 1
Antibody Name	Undisclosed
Antigen Name	AG7	Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed

2027 Update

The disease landscape of This ADC

2027 Update

The clinical trial pipelines of This ADC

Disease Name

Phase 1

Phase 2

Phase 3

Approved

Gastric cancer

1 Trials

Clinical trial identifier
NCT01466569

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT01466569	PHASE1	A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Eligible patients must be ≥18 years with ECOG ≤2; Phase 1a requires advanced epithelial solid tumors (failed prior chemo), Phase 1b requires recurrent/metastatic gastric cancer (chemo-naïve or failed prior chemo), with adequate organ function and life expectancy ≥3 months. Exclusions include CNS metastases, recent chemo/radiation/surgery, active infections, uncontrolled diabetes, significant cardiac history, or concurrent investigational therapies. Click to Show/Hide
Administration Dosage	Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
*Related Clinical Trial*
NCT Number	NCT01466569	Clinical Status	PHASE1
Clinical Description	A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Primary Endpoint	Safety evaluation includes adverse events (AEs), clinical lab tests, and physical exams over 10 weeks, focusing on treatment-emergent AEs and their severity.
Other Endpoint	Pharmacokinetic analysis at 3 dose levels (Phase 1a) and 2 dose levels (Phase 1b), with immunogenicity assessment (anti-drug antibodies) and tumor response per RECIST criteria, monitored over 10-12 weeks

References

Ref 1	An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors